Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.19
0.463.39%
Pre-Market: Mar 25, 9:20 AM EDT
Comments
Loading...
Benitec Biopharma Analyst Ratings and Price Targets | NASDAQ:BNTC | Benzinga
Benitec Biopharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Benitec Biopharma Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citizens Capital Markets
Baird
Guggenheim
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Benitec Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/24/2025 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | — | Citizens Capital Markets | Silvan Tuerkcan46% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/21/2025 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | — | Baird | Brian Skorney57% | → $30 | Initiates | → Outperform | Get Alert |
| 12/03/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay53% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | — | Oppenheimer | Andreas Argyrides69% | → $35 | Initiates | → Outperform | Get Alert |
| 10/14/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $16 → $18 | Maintains | Market Outperform | Get Alert |
| 09/30/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $16 → $16 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/12/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay53% | → $17 | Initiates | → Buy | Get Alert |
| 07/22/2024 | Buy Now | — | Leerink Partners | Mani Foroohar46% | → $13 | Initiates | → Outperform | Get Alert |
| 06/13/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi60% | → $30 | Initiates | → Overweight | Get Alert |
| 04/22/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $10 → $16 | Maintains | Market Outperform | Get Alert |
| 02/15/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $8 → $10 | Maintains | Market Outperform | Get Alert |
| 01/24/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $6 → $8 | Maintains | Market Outperform | Get Alert |
| 09/26/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $4 → $6 | Maintains | Market Outperform | Get Alert |
| 06/26/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | → $68 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/18/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | $68 → $68 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 10/18/2022 | Buy Now | — | JMP Securities | Silvan Tuerkcan46% | → $68 | Initiates | → Market Outperform | Get Alert |
| 09/23/2022 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio48% | $170 → $68 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Benitec Biopharma (BNTC) stock?
The latest price target for Benitec Biopharma (NASDAQ:BNTC) was reported by HC Wainwright & Co. on March 24, 2025. The analyst firm set a price target for $28.00 expecting BNTC to rise to within 12 months (a possible 97.32% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Benitec Biopharma (BNTC)?
The latest analyst rating for Benitec Biopharma (NASDAQ:BNTC) was provided by HC Wainwright & Co., and Benitec Biopharma reiterated their buy rating.
When was the last upgrade for Benitec Biopharma (BNTC)?
There is no last upgrade for Benitec Biopharma
When was the last downgrade for Benitec Biopharma (BNTC)?
There is no last downgrade for Benitec Biopharma.
When is the next analyst rating going to be posted or updated for Benitec Biopharma (BNTC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Benitec Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Benitec Biopharma was filed on March 24, 2025 so you should expect the next rating to be made available sometime around March 24, 2026.
Is the Analyst Rating Benitec Biopharma (BNTC) correct?
While ratings are subjective and will change, the latest Benitec Biopharma (BNTC) rating was a reiterated with a price target of $28.00 to $28.00. The current price Benitec Biopharma (BNTC) is trading at is $14.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.